Abstract
Background: Respiratory failure and thromboembolism are frequent in severe acute respiratory syndrome coronavirus 2-infected patients. Vitamin K activates both hepatic coagulation factors and extrahepatic endothelial anticoagulant protein S, required for thrombosis prevention. In times of vitamin K insufficiency, hepatic procoagulant factors are preferentially activated over extrahepatic proteins. Vitamin K also activates matrix Gla protein (MGP), which protects against pulmonary and vascular elastic fiber damage. We hypothesized that vitamin K may be implicated in coronavirus disease 2019 (COVID-19), linking pulmonary and thromboembolic disease. Methods: A total of 135 hospitalized COVID-19 patients were compared with 184 historic controls. Inactive vitamin K-dependent MGP (desphospho-uncarboxylated [dp-uc] MGP) and prothrombin (PIVKA-II) were measured inversely related to extrahepatic and hepatic vitamin K status, respectively. Desmosine was measured to quantify the rate of elastic fiber degradation. Arterial calcification severity was assessed using computed tomography. Results: dp-ucMGP was elevated in COVID-19 patients compared with controls (P
Author supplied keywords
Cite
CITATION STYLE
Dofferhoff, A. S. M., Piscaer, I., Schurgers, L. J., Visser, M. P. J., Van Den Ouweland, J. M. W., De Jong, P. A., … Janssen, R. (2021). Reduced Vitamin K Status as a Potentially Modifiable Risk Factor of Severe Coronavirus Disease 2019. Clinical Infectious Diseases, 73(11), E4039–E4046. https://doi.org/10.1093/cid/ciaa1258
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.